TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00661895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: 50 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 80 mg tablets \& 160 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 80 mg tablets \& 160 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: 4 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: 4 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 0.2 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 0.2 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: 50 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: 50 mg tablet \& 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Description: 50 mg tablet \& 100 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5 mg tablets \& 10 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg tablets \& 10 mg tablets
Study: NCT04149600

Intervention type: PROCEDURE
Intervention: Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.
Description: Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.

Intervention type: PROCEDURE
Intervention: Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.
Description: Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
Study: NCT02428946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: Investigating the randomized order for timing of bromocriptine administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: Investigating the randomized order for timing of bromocriptine administration
Study: NCT00408005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV
Study: NCT03541018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of repositional maneuvre
Description: Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of repositional maneuvre
Description: Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
Study: NCT02165020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Macrolane VRF 30®, Q-MED)
Description: One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle.
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given IV or PO
Study: NCT02357901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBOXONE
Description: SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBOXONE
Description: SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBOXONE
Description: SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBOXONE
Description: SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
Study: NCT01203046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Ertapenem 1 gr endovenous 3 or 7 days
Study: NCT01005914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Day 1-3: 50mg IV BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Day 3/Day4: 2,500 IU/ m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Day 4 \& 11: 2 mg IV
Study: NCT02707952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Co-formulated tablet
Study: NCT01203046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Ertapenem 1 gr endovenous 3 or 7 days
Study: NCT01319812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astron Stents
Description: Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsar Stents
Description: Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
Study: NCT04371679

Intervention type: OTHER
Intervention: No interventions planned
Description: No interventions planned. Observational.

Intervention type: OTHER
Intervention: No interventions planned
Description: No interventions planned. Observational.
Study: NCT02861794

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Medacta International, GMK Sphere medially stabilized knee
Description: Total Knee Replacement
Study: NCT03559153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shiatsu massage
Description: The shiatsu massage will be during the rest break by 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: The Physical Exercise will be during the rest break by 15 minutes.
Study: NCT04463550

Intervention type: OTHER
Intervention: Description and analysis
Description: Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given IV or PO

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Some patients undergo testicular and/or prophylactic cranial RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Some patients undergo testicular and/or prophylactic cranial RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Some patients undergo testicular and/or prophylactic cranial RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Some patients undergo testicular and/or prophylactic cranial RT
Study: NCT02707952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Co-formulated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OBV/PTV/r
Description: Co-formulated tablet
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01633892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Study: NCT00963287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bascial prescription plus or minus herbs depend on symptoms
Description: Decoction ,two times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bascial prescription plus or minus herbs depend on symptoms
Description: Decoction ,two times a day
Study: NCT02116400

Intervention type: OTHER
Intervention: Interview
Description: All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.

Intervention type: OTHER
Intervention: Interview
Description: All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.

Intervention type: OTHER
Intervention: Neuropsychological testing
Description: Neuropsychological tests are administered (requires computer use). See endpoints.

Intervention type: OTHER
Intervention: Neuropsychological testing
Description: Neuropsychological tests are administered (requires computer use). See endpoints.

Intervention type: BIOLOGICAL
Intervention: Serum concentration of lithium or sodium divalproate.
Description: Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.

Intervention type: BIOLOGICAL
Intervention: Serum concentration of lithium or sodium divalproate.
Description: Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
Study: NCT02402309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active topical NS2 1% dermatologic cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle placebo 0.0% NS2 dermatologic cream
Study: NCT03854617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral NVB Metronomic
Description: 50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral NVB Weekly
Description: 60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
Study: NCT04853745

Intervention type: DEVICE
Intervention: AIR-FLOW® Master Piezon
Description: AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.

Intervention type: DEVICE
Intervention: AIR-FLOW® Master Piezon
Description: AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.

Intervention type: DEVICE
Intervention: AIR-FLOW® Master Piezon
Description: AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
Study: NCT02307357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical fitness tests
Description: the subjects will perform 6 different tests to evaluate their physical fitness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical fitness tests
Description: the subjects will perform 6 different tests to evaluate their physical fitness
Study: NCT00687765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 plus temozolomide
Description: BSI-201 given iv. 2x weekly, temozolomide given orally
Study: NCT01701843

Intervention type: DRUG
Group type: OTHER
Intervention: Cromoglicate
Description: Twice daily topical treatment for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Cromoglicate
Description: Twice daily topical treatment for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Twice daily topical treatment for 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Twice daily topical treatment for 14 days
Study: NCT04517565

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain magnetic resonance imaging
Description: Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-psychology testing
Description: Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
Study: NCT04659850

Intervention type: OTHER
Group type: OTHER
Intervention: low fat, low AGE milkshake
Description: low fat, low AGE milkshake given after an overnight fast

Intervention type: OTHER
Group type: OTHER
Intervention: low fat, low AGE milkshake
Description: low fat, low AGE milkshake given after an overnight fast

Intervention type: OTHER
Group type: OTHER
Intervention: low fat, high AGE milkshake
Description: low fat, high AGE milkshake given after an overnight fast

Intervention type: OTHER
Group type: OTHER
Intervention: low fat, high AGE milkshake
Description: low fat, high AGE milkshake given after an overnight fast

Intervention type: OTHER
Group type: OTHER
Intervention: high fat, low AGE
Description: high fat, low AGE milkshake given after an overnight fast

Intervention type: OTHER
Group type: OTHER
Intervention: high fat, low AGE
Description: high fat, low AGE milkshake given after an overnight fast

Intervention type: OTHER
Group type: OTHER
Intervention: high fat, high AGE milkshake
Description: high fat, high AGE milkshake given after an overnight fast

Intervention type: OTHER
Group type: OTHER
Intervention: high fat, high AGE milkshake
Description: high fat, high AGE milkshake given after an overnight fast
Study: NCT02631850

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CI Therapy
Description: Intensive in-person therapy for upper extremity hemiparesis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming CI Therapy
Description: Intensive remote (via video game) therapy for upper extremity hemiparesis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming CI Therapy with Additional Contact via Video Conference
Description: Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Occupational Therapy/Physical Therapy
Description: Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
Study: NCT01001507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated family planning/HIV care and treatment services
Description: Family planning services will be provided during the patient's HIV care visit.
Study: NCT02347267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric and non-caloric SSBS reduction
Description: Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric SSBS reduction
Description: Isocaloric individualized diet and caloric SSBS restriction
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04473365

Intervention type: OTHER
Intervention: Intestinal parasite
Description: Pre-existing intestinal parasite infection present or absent at time of admission
Study: NCT03417596

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Routine treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Routine treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: Exercise and rehabilitation programme was individualized

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: Exercise and rehabilitation programme was individualized
Study: NCT02981524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY is administered intravenously at 200 mg/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered intravenously at 200 mg
Study: NCT01101698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2+10μg cholecalciferol
Description: Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2+10μg cholecalciferol
Description: Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months